Home › Funds › Rock Springs Capital Management LP › XENE
Rock Springs Capital Management LP position in XENE
XENON PHARMACEUTICALS INC · Health Care
Rock Springs Capital Management LP reported holding 524,758 shares of XENE (XENON PHARMACEUTICALS INC) in its Q3 2026 13F filing — a position valued at US$19.5M, representing 1.06% of its reported portfolio and ranking #29 among its reported holdings. Rock Springs Capital Management LP has disclosed XENE holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR
How Rock Springs Capital Management LP's XENE position evolved
Rock Springs Capital Management LP first disclosed a stake in XENE in Q3 2023 at 1,178,002 shares (US$40.2M). The position peaked in Q4 2023 at 1,255,577 shares, worth US$57.8M. Across 13 filings, Rock Springs Capital Management LP increased the stake 3 time(s), trimmed it 7 time(s) and left it unchanged 2 time(s). The most recent filing (Q3 2026) shows 524,758 shares valued at US$19.5M — a reduction of -159,149 shares quarter over quarter.. Notable position changes include a 26% trim in Q1 2025 (shares fell 7% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 1.18M | $40.24M | New |
| Q4 2023 | 1.26M | $57.83M | Add |
| Q1 2024 | 1.26M | $54.05M | Hold |
| Q2 2024 | 1.27M | $49.63M | Add |
| Q3 2024 | 1.32M | $51.83M | Add |
| Q4 2024 | 1.25M | $49.07M | Reduce |
| Q1 2025 | 931.68K | $31.26M | Reduce |
| Q2 2025 | 931.68K | $29.16M | Hold |
| Q3 2025 | 851.74K | $34.20M | Reduce |
| Q4 2025 | 787.79K | $35.31M | Reduce |
| Q1 2026 | 763.02K | $44.37M | Reduce |
| Q2 2026 | 683.91K | $41.28M | Reduce |
| Q3 2026 | 524.76K | $19.52M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About XENE and 13F data
XENE (XENON PHARMACEUTICALS INC) is a Health Care company. 32 other funds we track also report a position in XENE — the largest reported positions include Avoro Capital Advisors LLC (US$204.5M), DRIEHAUS CAPITAL MANAGEMENT LLC (US$132.3M), DEERFIELD MANAGEMENT COMPANY, L.P. (US$97.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding XENE
- Avoro Capital Advisors LLC 5.50M sh · $204.54M · Q3 2026
- DRIEHAUS CAPITAL MANAGEMENT LLC 3.56M sh · $132.31M · Q3 2026
- DEERFIELD MANAGEMENT COMPANY, L.P. 1.62M sh · $97.52M · Q2 2026
- Affinity Asset Advisors, LLC 1.90M sh · $70.67M · Q3 2026
- BRAIDWELL LP 1.13M sh · $68.29M · Q2 2026
- ORBIMED ADVISORS LLC 892.47K sh · $53.87M · Q2 2026
- Caligan Partners LP 889.94K sh · $53.72M · Q2 2026
- Vestal Point Capital, LP 700.00K sh · $42.25M · Q2 2026
More on Rock Springs Capital Management LP
FAQ
How long has Rock Springs Capital Management LP held XENE?
Rock Springs Capital Management LP has disclosed XENE holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
What is Rock Springs Capital Management LP's current position in XENE?
As of Q3 2026, Rock Springs Capital Management LP holds 524.76K shares of XENE (XENON PHARMACEUTICALS INC), valued at $19.52M, representing 1.06% of its reported portfolio and ranking #29.
Has Rock Springs Capital Management LP been buying or selling XENE?
In the latest 13F filing (Q3 2026), Rock Springs Capital Management LP reduced its position in XENE. The position peaked in Q4 2023 at 1.26M shares.
Which other funds hold XENE?
Other major institutional holders of XENE include Avoro Capital Advisors LLC, DRIEHAUS CAPITAL MANAGEMENT LLC, DEERFIELD MANAGEMENT COMPANY, L.P., among 32 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.